News GW files cannabis-based epilepsy drug in EU and US After Sativex disappointment, Epidiolex could transform GW's fortunes.
News GW prepares for 2018 US launch of epilepsy drug But Zynerba's cannabis epilepsy drug fails in phase 2.
News GW close to filing cannabis-based epilepsy drug Epidiolex could become a blockbuster if approved in all uses.
News GW could be next big pharma takeover target UK firm has hired bankers to deal with approaches - press reports.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
